Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

about

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer

P2860

Q55037961-689210A4-D919-4A86-B3B9-3EF8F8C277EB Q57074267-34DE5367-BCD9-46B5-AB88-C4AD8E8CE3E1

P2860

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

Item

http://www.wikidata.org/entity/Q44096551

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@en

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@nl

type

Item

label

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@en

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@nl

prefLabel

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@en

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@nl

P1476

Meta-analysis of individual pa ...... noclonal antibody ramucirumab.

@en

P2093

A D Baron

http://www.w3.org/2001/XMLSchema#string

A Ohtsu

http://www.w3.org/2001/XMLSchema#string

A Sashegyi

http://www.w3.org/2001/XMLSchema#string

A X Zhu

http://www.w3.org/2001/XMLSchema#string

C S Fuchs

http://www.w3.org/2001/XMLSchema#string

D Arnold

http://www.w3.org/2001/XMLSchema#string

D Ferry

http://www.w3.org/2001/XMLSchema#string

E B Garon

http://www.w3.org/2001/XMLSchema#string

H H Yoon

http://www.w3.org/2001/XMLSchema#string

I Chau

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Management and preparedness for infusion and hypersensitivity reactions.

Perspectives on making big data analytics work for oncology.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies.

Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.

P304

2932-2942

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

meta-analysis

P356

10.1093/ANNONC/MDX514

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28950290

http://www.w3.org/2001/XMLSchema#string

P921

P932

5834052

http://www.w3.org/2001/XMLSchema#string

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

about

P2860

P2860

Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932